TP53 and cancer: Indeed, previous investigations have demonstrated that when cancer cell lines with wild-type p53 status are treated in vitro for a prolonged period with nutlin-3, a potent and specific MDM2 inhibitor, tumor cells acquire inactivating p53 mutation(s), which renders p53 non-functional and results in profound acquired resistance to the drug[23–26].